ClinicalTrials.gg

Program

LM-168

A development code.

In Sino Biopharmaceutical's pipeline, CTLA-4TME单抗. Its studies are led by Sino Biopharmaceutical.

Furthest: phase 2, since Feb 6, 20252 company-led studies, 2 open or runningNext primary completion: Aug 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical22 open or runningphase 2since Feb 6, 2025Feb 6, 2025Aug 1, 2027phase 2 · NCT06868199
  • Named in Sino Biopharmaceutical’s own pipeline as LM-168, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 6, 2025First study: phase 2 study in Advanced Solid TumoursFirst studyNCT06868199 · 87 planned · Australia, China
  2. Jun 10, 2026Phase 2 study in Advanced Solid TumorNCT07669415 · 108 planned · China

Ahead

  1. Aug 1, 2027Primary completion: phase 2 study in Advanced Solid TumoursNCT06868199
  2. Dec 15, 2027Primary completion: phase 2 study in Advanced Solid TumorNCT07669415

TargetBeta

“CTLA-4TME单抗”the company's pipeline, read by Claude · source

Other programs on CTLA4

ProgramCompanyFurthest phaseStudies
tremelimumabruleAstraZenecaphase 347
cadonilimabruleAkesophase 345
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
Anti-CTLA-4 Monoclonal Antibody SHR-8068ruleJiangsu HengRui Medicinephase 316
erfonrilimabruleAlphamab Oncologyphase 314
Anti-CTLA-4 Monoclonal Antibody IBI310ruleInnovent Biologicsphase 311
gotistobartruleoncoc4-incphase 35
zalifrelimabruleAgenusphase 26
porustobartruleharbour-biomed-guangzhou-co-ltdphase 25
lorigerlimabruleMacroGenicsphase 24
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07669415Advanced Solid Tumor · China2RecruitingDec 15, 2027108
NCT06868199Advanced Solid Tumours · Australia, China2RecruitingAug 1, 202787

How it is read

Names in the registry

  • “LM-168”, 2 entries

Codes read as this program: LM168.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.